Recommendations for raloxifene use in daily clinical practice in the Swiss setting

Lippuner, Kurt; Buchard, P A; De Geyter, C; Imthurn, B; Lamy, O; Litschgi, M; Luzuy, F; Schiessl, K; Stute, P; Birkhäuser, M (2012). Recommendations for raloxifene use in daily clinical practice in the Swiss setting. European spine journal, 21(12), pp. 2407-17. Berlin: Springer-Verlag 10.1007/s00586-012-2404-y

[img]
Preview
Text
586_2012_Article_2404.pdf - Published Version
Available under License Publisher holds Copyright.

Download (285kB) | Preview

Raloxifene is the first selective estrogen receptor modulator that has been approved for the treatment and prevention of osteoporosis in postmenopausal women in Europe and in the US. Although raloxifene reduces the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer, it is approved in that indication in the US but not in the EU. The aim was to characterize the clinical profiles of postmenopausal women expected to benefit most from therapy with raloxifene based on published scientific evidence to date.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Orthopaedic, Plastic and Hand Surgery (DOPH) > Clinic of Osteoporosis
04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Gynaecology

UniBE Contributor:

Lippuner, Kurt; Stute, Petra and Birkhäuser, Martin

ISSN:

0940-6719

Publisher:

Springer-Verlag

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:24

Last Modified:

26 Jun 2018 14:35

Publisher DOI:

10.1007/s00586-012-2404-y

PubMed ID:

22739699

Web of Science ID:

000311780000001

BORIS DOI:

10.7892/boris.8673

URI:

https://boris.unibe.ch/id/eprint/8673 (FactScience: 214285)

Actions (login required)

Edit item Edit item
Provide Feedback